Skip to content

Clinical Performance of the AFGen1 Device Over a 7-day Period

Clinical Performance of the AFGen1 Device Over a 7-day Period

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05295056
Enrollment
38
Registered
2022-03-24
Start date
2022-05-12
Completion date
2023-08-25
Last updated
2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Afib, Arrhythmia Atrial, Arrhythmias, Cardiac, Arrhythmias Paroxysmal, Atrial Fibrillation, Irregular Heart Beat, Paroxysmal Atrial Fibrillation

Brief summary

AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. The purpose of this study is to establish the clinical performance of the AFib-Chek device (a.k.a. Device) on human participants.

Detailed description

The primary purpose of this study is to demonstrate that the ECD signal acquired by the AFGen1 device is as of adequate quality and is suitable to support its intended use for the detection of AFib.

Interventions

DEVICEAFGen1 Device Wear Test

Participant wears the device for 7 days

DEVICEAFGen 1 Device Single Use

Participant wears the device in conjunction with a standard ECG

Sponsors

TriVirum, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to 90 Years

Inclusion criteria

1\. 18+ willing to sign the consent form

Exclusion criteria

1. Implanted pacemakers 2. Implanted cardioverter defibrillators 3. Implanted cardiac resynchronization devices 4. Potential life-threatening arrythmias 5. Physical or mental health conditions that would prevent the person from being able to follow instruc-tions regarding participation in the study 6. Open wounds, abraded or irritated skin at the application site 7. Planned to undergo a MRI during the course of the study duration

Design outcomes

Primary

MeasureTime frameDescription
Quantitative Evaluation7 daysFor the quantitative evaluation of the mean and standard deviation of the QRS correlations for all study subjects and for the end of the wear period for those relevant subjects, the mean cor- relation coefficient must be greater than 0.95 and standard deviation must be less than 0.05 to validate a 95% confidence interval with significant factor of assurance.
Qualitative Equivalence Evaluation7 daysFor the qualitative equivalence evaluation according to the two cardiologists the confirmation of equivalence must be greater than 95%.
Adhesive performance7 daysFor the adhe sive performance element of the stud y; t he overall average wear time for the de- vice must be greater than 5 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026